These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease. Tiberia E, Turnbull J, Wang T, Ruggieri A, Zhao XC, Pencea N, Israelian J, Wang Y, Ackerley CA, Wang P, Liu Y, Minassian BA. J Biol Chem; 2012 Jul 20; 287(30):25650-9. PubMed ID: 22669944 [Abstract] [Full Text] [Related]
24. Loss of malin, but not laforin, results in compromised autophagic flux and proteasomal dysfunction in cells exposed to heat shock. Jain N, Rai A, Mishra R, Ganesh S. Cell Stress Chaperones; 2017 Mar 20; 22(2):307-315. PubMed ID: 27975203 [Abstract] [Full Text] [Related]
25. Deciphering the role of malin in the lafora progressive myoclonus epilepsy. Romá-Mateo C, Sanz P, Gentry MS. IUBMB Life; 2012 Oct 20; 64(10):801-8. PubMed ID: 22815132 [Abstract] [Full Text] [Related]
26. Ubiquitin conjugating enzyme E2-N and sequestosome-1 (p62) are components of the ubiquitination process mediated by the malin-laforin E3-ubiquitin ligase complex. Sánchez-Martín P, Romá-Mateo C, Viana R, Sanz P. Int J Biochem Cell Biol; 2015 Dec 20; 69():204-14. PubMed ID: 26546463 [Abstract] [Full Text] [Related]
28. Accumulation of Laforin and Other Related Proteins in Canine Lafora Disease With EPM2B Repeat Expansion. Chambers JK, Thongtharb A, Shiga T, Azakami D, Saito M, Sato M, Morozumi M, Nakayama H, Uchida K. Vet Pathol; 2018 Jul 20; 55(4):543-551. PubMed ID: 29444631 [Abstract] [Full Text] [Related]
29. Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy. Chan EM, Ackerley CA, Lohi H, Ianzano L, Cortez MA, Shannon P, Scherer SW, Minassian BA. Hum Mol Genet; 2004 Jun 01; 13(11):1117-29. PubMed ID: 15102711 [Abstract] [Full Text] [Related]
31. Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes. Ganesh S, Agarwala KL, Ueda K, Akagi T, Shoda K, Usui T, Hashikawa T, Osada H, Delgado-Escueta AV, Yamakawa K. Hum Mol Genet; 2000 Sep 22; 9(15):2251-61. PubMed ID: 11001928 [Abstract] [Full Text] [Related]
32. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease. Ardley HC, Scott GB, Rose SA, Tan NG, Robinson PA. J Neurochem; 2004 Jul 22; 90(2):379-91. PubMed ID: 15228595 [Abstract] [Full Text] [Related]
37. Laforin, a protein with many faces: glucan phosphatase, adapter protein, et alii. Gentry MS, Romá-Mateo C, Sanz P. FEBS J; 2013 Jan 22; 280(2):525-37. PubMed ID: 22364389 [Abstract] [Full Text] [Related]
38. Lafora Disease: A Ubiquitination-Related Pathology. García-Gimeno MA, Knecht E, Sanz P. Cells; 2018 Jul 26; 7(8):. PubMed ID: 30050012 [Abstract] [Full Text] [Related]
39. Modulation of functional properties of laforin phosphatase by alternative splicing reveals a novel mechanism for the EPM2A gene in Lafora progressive myoclonus epilepsy. Dubey D, Ganesh S. Hum Mol Genet; 2008 Oct 01; 17(19):3010-20. PubMed ID: 18617530 [Abstract] [Full Text] [Related]
40. Laforin targets malin to glycogen in Lafora progressive myoclonus epilepsy. Mitra S, Chen B, Wang P, Chown EE, Dear M, Guisso DR, Mariam U, Wu J, Gumusgoz E, Minassian BA. Dis Model Mech; 2023 Jan 01; 16(1):. PubMed ID: 36511140 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]